Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis (AMEND)
Psychosis, Negative Symptoms With Primary Psychotic Disorder
About this trial
This is an interventional treatment trial for Psychosis focused on measuring Memantine, Aripiprazole, 7 tesla MR
Eligibility Criteria
Inclusion Criteria:
Patients:
- Antipsychotic-naïve, first episode psychosis
- Fulfilling the diagnostic criteria of schizophrenia, persistent delusional disorder, acute and transient psychotic disorders, schizoaffective disorder, other non-organic psychotic disorders and unspecified non-organic disorders (ICD-10: F20.x; F22.x; F23.x; F24.x; F25.x; F28; F29); verified by PSE interview.
- Age: 18-45 years
- Legally competent (In Danish: 'myndige og habile i retslig forstand')
Healthy controls:
- No first-degree relative with known major psychiatric disorder (ICD-10: F1x; F2x; F3x)
- Age 18-45 years
- Legally competent (In Danish: 'myndige og habile i retslig forstand')
Exclusion Criteria:
Patients
- Prior use of antipsychotic medication
- Treatment with antidepressant medication the last 7 days
- Current substance dependence ICD-10 (F1x.2) or substance abuse in any period up to 3 months prior to referral (exception: tobacco/nicotine, F17.2)
- Head injury with more than 5 minutes of unconsciousness, lifetime
- Any coercive measure
- Metal implanted by operation
- Head or neck tattoos
- Pacemaker
- Pregnancy (assessed by urine HCG)
- Female patients: Unwillingness to use safe contraception (Intra Uterine Device/System or hormonal contraceptives) during the study period.
- Severe physical illness
- Allergies to any of the ingredients in the amisulpride tablets or memantine tablets
Healthy controls:
- Lifetime substance abuse/dependence ICD-10 (F1x.1/F1x.2) (exception: tobacco/nicotine, F17.1/F17.2)
- Lifetime treatment with antidepressants
- Head injury with more than 5 minutes of unconsciousness
- Metal implanted by operation
- Head or neck tattoos
- Pacemaker
- Pregnancy (assessed by urine HCG)
- Severe physical illness
Sites / Locations
- Centre for Neuropsychiatric Schizophrenia Research, CNSR & Centre for Clinical Intervention & Neuropsychiatric Schizophrenia Research, CINSRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Memantine + aripiprazole
Placebo + aripiprazole
Tablet memantine or placebo will be initiated at 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. The tablets will be identical and be provided in 10mg tablets or 20 mg tablets. (12 weeks of treatment). Tablet aripiprazole will be administered in doses starting at 5-10 mg/day. Doses will be increased slowly according to effect and side effects up to 30 mg/day.
Coated placebo tablets will be provided to match memantine. Placebo equivalent of 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. (12 weeks of treatment). Tablet aripiprazole will be administered in doses starting at 5-10 mg/day. Doses will be increased slowly according to effect and side effects up to 30 mg/day.